Calendar

Apr
22
Wed
2020
IBIIS/AIMI Seminar - Tiwari @ ZOOM - See Description for Zoom link
IBIIS/AIMI Seminar – Tiwari
Apr 22 @ 1:00 pm – 2:00 pm ZOOM - See Description for Zoom link
IBIIS/AIMI Seminar - Tiwari @ ZOOM - See Description for Zoom link

Radiomics and Radio-Genomics: Opportunities for Precision Medicine

Zoom: https://stanford.zoom.us/j/99904033216?pwd=U2tTdUp0YWtneTNUb1E4V2x0OTFMQT09 

Pallavi Tiwari, PhD
Assistant Professor of Biomedical Engineering
Associate Member, Case Comprehensive Cancer Center
Director of Brain Image Computing Laboratory
School of Medicine | Case Western Reserve University


Abstract:
In this talk, Dr. Tiwari will focus on her lab’s recent efforts in developing radiomic (extracting computerized sub-visual features from radiologic imaging), radiogenomic (identifying radiologic features associated with molecular phenotypes), and radiopathomic (radiologic features associated with pathologic phenotypes) techniques to capture insights into the underlying tumor biology as observed on non-invasive routine imaging. She will focus on clinical applications of this work for predicting disease outcome, recurrence, progression and response to therapy specifically in the context of brain tumors. She will also discuss current efforts in developing new radiomic features for post-treatment evaluation and predicting response to chemo-radiation treatment. Dr. Tiwari will conclude with a discussion on her lab’s findings in AI + experts, in the context of a clinically challenging problem of post-treatment response assessment on routine MRI scans.

Apr
24
Fri
2020
Mini-Grand Rounds - Ann Leung, MD @ Zoom
Mini-Grand Rounds – Ann Leung, MD
Apr 24 @ 7:00 am – 7:30 am Zoom
Mini-Grand Rounds - Ann Leung, MD @ Zoom

Mini-Grand Rounds: Stanford University Medical Center and COVID-19: A Chest Radiologist’s Perspective

Ann Leung, MD
Associate Chair, Clinical Affairs
Professor, Radiology

7:00am – 7:30am, Zoom

The Stanford Radiology Mini-Grand Round live session events are by invitation only. Invites with link to Zoom video will be sent via email to Department faculty and staff only. Recordings will be made available to the public shortly after the event.

Apr
27
Mon
2020
Mini-Grand Rounds - David Larson, MD, MBA @ Zoom
Mini-Grand Rounds – David Larson, MD, MBA
Apr 27 @ 7:00 am – 7:30 am Zoom
Mini-Grand Rounds - David Larson, MD, MBA @ Zoom

Mini-Grand Rounds: The Outlook for Radiology in the Next Phases of the Pandemic and Beyond

David Larson, MD, MBA
Vice Chair, Education and Clinical Operations
Associate Professor, Radiology

7:00am – 7:30am, Zoom

The Stanford Radiology Mini-Grand Round live session events are by invitation only. Invites with link to Zoom video will be sent via email to Department faculty and staff only. Recordings will be made available to the public shortly after the event.

May
26
Tue
2020
Cancer Early Detection Seminar Series - Eric Fung, M.D., Ph.D. @ Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series – Eric Fung, M.D., Ph.D.
May 26 @ 11:00 am – 12:00 pm Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series - Eric Fung, M.D., Ph.D. @ Zoom - See Description for Zoom Link

CEDSS: “Multicancer detection of early-stage cancers with simultaneous tissue localization using a plasma cfDNA-based targeted methylation assay”

Eric Fung, M.D., Ph.D.

Senior Medical Director

GRAIL, Inc.

Please see zoom details below:
Meeting URL: https://stanford.zoom.us/j/230531527
Dial: +1 650 724 9799 (US, Canada, Caribbean Toll) or +1 833 302 1536 (US, Canada, Caribbean Toll Free)
Meeting ID: 230 531 527

ABOUT

Dr. Eric Fung is Vice President, Clinical Development at GRAIL, where he leads several clinical development programs in support of the development of a blood-based multi-cancer detection test. Dr. Fung has previously held clinical development and R&D leadership roles at Affymetrix, Vermillion, Ciphergen, and Roche Molecular Diagnostics. Dr. Fung has led clinical trials leading to FDA clearance of multiple IVD products. Dr. Fung received his MD, PhD from the Johns Hopkins University School of Medicine.

 

Hosted by: Sanjiv Sam Gambhir, M.D., Ph.D.
Spon
sored by the Canary Center & the Department of Radiology 
Stanford University – School of Medicine

Oct
15
Thu
2020
Cancer Early Detection Seminar Series - Paul Boutros, Ph.D., M.B.A. @ Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series – Paul Boutros, Ph.D., M.B.A.
Oct 15 @ 11:00 am – 12:00 pm Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series - Paul Boutros, Ph.D., M.B.A. @ Zoom - See Description for Zoom Link

CEDSS: “The Origins and Detection of Lethal Prostate Cancer”

Paul Boutros, Ph.D., M.B.A.
Director, Cancer Data Sciences
UCLA

Please see zoom details below:
Meeting URL: https://stanford.zoom.us/s/93515779500
Dial: +1 650 724 9799 or +1 833 302 1536
Meeting ID: 935 1577 9500
Meeting Passcode: 767148

ABOUT
Boutros earned his B.Sc. degree from the University of Waterloo in Chemistry in 2004, and his Ph.D. degree from the University of Toronto, Canada, in Medical Biophysics in 2008. At Toronto, he also earned an executive M.B.A. from the Rothman School of Management. In 2008, Boutros started his independent research career at the Ontario Institute for Cancer Research first as a fellow (2008–2010) and then as principal investigator (2010–2018). He moved to California to join the UCLA faculty in 2018.

 

Hosted by: Utkan Demirci, Ph.D.
Spon
sored by the Canary Center & the Department of Radiology 
Stanford University – School of Medicine

Nov
18
Wed
2020
IBIIS & AIMI Seminar: Deep Tomographic Imaging @ Zoom: https://stanford.zoom.us/j/96731559276?pwd=WG5zcEFwSGlPcDRsOUFkVlRhcEs2Zz09
IBIIS & AIMI Seminar: Deep Tomographic Imaging
Nov 18 @ 12:00 pm – 1:00 pm Zoom: https://stanford.zoom.us/j/96731559276?pwd=WG5zcEFwSGlPcDRsOUFkVlRhcEs2Zz09

Ge Wang, PhD
Clark & Crossan Endowed Chair Professor
Director of the Biomedical Imaging Center
Rensselaer Polytechnic Institute
Troy, New York

Abstract:
AI-based tomography is an important application and a new frontier of machine learning. AI, especially deep learning, has been widely used in computer vision and image analysis, which deal with existing images, improve them, and produce features. Since 2016, deep learning techniques are actively researched for tomography in the context of medicine. Tomographic reconstruction produces images of multi-dimensional structures from externally measured “encoded” data in the form of various transforms (integrals, harmonics, and so on). In this presentation, we provide a general background, highlight representative results, and discuss key issues that need to be addressed in this emerging field.

About:
AI-based X-ray Imaging System (AXIS) lab is led by Dr. Ge Wang, affiliated with the Department of Biomedical Engineering at Rensselaer Polytechnic Institute and the Center for Biotechnology and Interdisciplinary Studies in the Biomedical Imaging Center. AXIS lab focuses on innovation and translation of x-ray computed tomography, optical molecular tomography, multi-scale and multi-modality imaging, and AI/machine learning for image reconstruction and analysis, and has been continuously well funded by federal agencies and leading companies. AXIS group collaborates with Stanford, Harvard, Cornell, MSK, UTSW, Yale, GE, Hologic, and others, to develop theories, methods, software, systems, applications, and workflows.

Jan
19
Tue
2021
Cancer Early Detection Seminar Series - Thomas Kislinger, Ph.D. @ Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series – Thomas Kislinger, Ph.D.
Jan 19 @ 11:00 am – 12:00 pm Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series - Thomas Kislinger, Ph.D. @ Zoom - See Description for Zoom Link

CEDSS: Systematic identification of fluid-based biomarkers for ovarian and prostate cancer

 

Thomas Kislinger, Ph.D.
Professor & Chair
Department of Medical Biophysics
University of Toronto

Senior Scientist
Princess Margaret Cancer Centre

 

Zoom Webinar Details 
Meeting URL: https://stanford.zoom.us/s/94878578384
Dial: +1 650 724 9799 or +1 833 302 1536
Webinar ID: 948 7857 8384
Passcode: 692692
Register Here

 

ABOUT

Thomas Kislinger received his MSc in Analytical Chemistry from the University of Munich, Germany (1998). He completed his PhD in 2001, investigating the role of Advanced Glycation Endproducts in diabetic vascular complications at the University of Erlangen, Germany and Columbia University, New York. Between 2002 and 2006 he completed a post-doctoral fellowship at the University of Toronto. In 2006 he joined the Princess Margaret Cancer Centre as an independent investigator. Dr. Kislinger holds positions as Senior Scientist at the Princess Margaret Cancer Centre and as Professor and Chair at the University of Toronto in the Department of Medical Biophysics. The Kislinger lab applies proteomics technologies to translational and basic cancer biology. This includes the development of novel proteomics methodologies, identification of liquid biopsy signatures and the molecular identification of novel cell surface markers.

 

Hosted by: Utkan Demirci, Ph.D.
Spon
sored by: The Canary Center & the Department of Radiology 
Stanford University – School of Medicine

Mar
2
Tue
2021
Cancer Early Detection Seminar Series - Melissa Wong, Ph.D. @ Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series – Melissa Wong, Ph.D.
Mar 2 @ 11:00 am – 12:00 pm Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series - Melissa Wong, Ph.D. @ Zoom - See Description for Zoom Link

CEDSS: Disseminated cell hybrids as biomarkers for cancer detection, prognosis and treatment response

Melissa Wong, Ph.D.
Associate Professor and Vice Chair
Department of Cell, Development and Cancer Biology
Program Co-Lead, Knight Cancer Institute
Oregon Health & Science University

 

Zoom Details
Meeting URL: https://stanford.zoom.us/s/98184098662
Dial: US: +1 650 724 9799  or +1 833 302 1536 (Toll Free)
Meeting ID: 981 8409 8662
Passcode: 084321

RSVP Here!

 

ABSTRACT

Metastatic progression defines the final stages of tumor evolution and underlies the majority of cancer-related deaths. The heterogeneity in disseminated tumor cell populations capable of seeding and growing in distant organ sites contributes to the development of treatment resistant disease.  We recently reported the identification of a novel tumor-derived cell population, circulating hybrid cells (CHCs), harboring attributes from both macrophages and neoplastic cells, including functional characteristics important to metastatic spread. These disseminated hybrids outnumber conventionally defined circulating tumor cells (CTCs) in cancer patients. It is unknown if CHCs represent a generalized cancer mechanism for cell dissemination, or if this population is relevant to the metastatic cascade. We detect CHCs in the peripheral blood of patients with cancer in myriad disease sites encompassing epithelial and non-epithelial malignancies. Further, we demonstrate that in vivo-derived hybrid cells harbor tumor-initiating capacity in murine cancer models and that CHCs from human breast cancer patients express stem cell antigens, features consistent with the ability to seed and grow at metastatic sites. We reveal heterogeneity of CHC phenotypes reflect key tumor features, including oncogenic mutations and functional protein expression. Importantly, this novel population of disseminated neoplastic cells opens a new area in cancer biology and renewed opportunity for battling metastatic disease.

 

ABOUT

The research focus of the Wong laboratory revolves around understanding the regulatory mechanisms that control epithelial stem cell homeostasis and their expansion in developmental, homeostasis and disease contexts, including cancer. I have substantial training and experience in intestinal stem cell investigation leveraging in vivo and ex vivo modeling, as well as in myriad cutting edge technologies (i.e. cyCIF, scRNA-seq). My publication record spans my post-doctoral fellowship in Dr. Jeffrey Gordon’s laboratory at Washington University School of Medicine, to studies in my own laboratory at Oregon Health & Science University. Our research impacts the understanding of regulatory mechanisms that govern cell state in the context of the evolving tissue microenvironment and changing cell signaling landscape, in development and disease.

 

Our studies in stem cell regulation led to the intriguing finding that stem cells can fuse with tissue macrophages in the context of injury repair and may impact tissue regeneration. We have extended these findings to the cancer setting, where cancer-macrophage fusions are detectible in primary and metastatic tumors, and my group recently identified and characterized these cells as a novel circulating tumor cell population. Importantly, our studies in cell culture, in mice and humans provide an indepth evaluation of hybrid cells to set the foundation for continued investigations into their biology, impact on disease progression or tissue regeneration, and use as a biomarker for disease burden. Importantly, we coined the term, circulating hybrid cell (CHC) for this novel population and reported they exist at higher levels than conventionally defined circulating tumor cells in the peripheral blood of cancer patients. This work was published in 2018 and highlighted by Science Magazine as one of the top ten publications in the cancer field in the science family journals. The science proposed in this U01 application leverage hybrid cell biology to assess treatment response and resistance in breast cancer patients undergoing targeted therapy. Our proposal leverages active collaborations with Dr. Young Hwan Young’s group to synergize biology with computation, as well as a number of other valuable collaborators to ensure success of the proposed, cutting-edge science.

 

Hosted by: Utkan Demirci, Ph.D.
Spon
sored by: The Canary Center & the Department of Radiology 
Stanford University – School of Medicine

May
11
Tue
2021
Cancer Early Detection Seminar Series - Michael Berger, Ph.D. @ Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series – Michael Berger, Ph.D.
May 11 @ 11:00 am – 12:00 pm Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series - Michael Berger, Ph.D. @ Zoom - See Description for Zoom Link

CEDSS: “Building a Scalable Clinical Genomics Program: How tumor, normal, and plasma DNA sequencing are informing cancer care, cancer risk, and cancer detection”

 

Michael Berger, Ph.D.

Elizabeth and Felix Rohatyn Chair & Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology
Memorial Sloan Kettering Cancer Center

 

Zoom Details
Meeting URL: https://stanford.zoom.us/s/92559505314
Dial: US: +1 650 724 9799  or +1 833 302 1536 (Toll Free)
Meeting ID: 925 5950 5314
Passcode: 418727

11:00am – 12:00pm Seminar & Discussion
RSVP Here

 

ABSTRACT
Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of oncogenomic mutations that can be targeted therapeutically. To accelerate enrollment to clinical trials of molecularly targeted agents and guide treatment selection, we have established a center-wide, prospective clinical sequencing program at Memorial Sloan Kettering Cancer Center using a custom, paired tumor-blood normal sequencing assay (MSK-IMPACT), which we have used to profile more than 50,000 patients with solid tumors. Yet beyond just the characterization of tumor-specific alterations, the inclusion of blood DNA has readily enabled the identification of germline risk alleles and somatic mutations associated with clonal hematopoiesis. To complement this approach, we have also implemented a ‘liquid biopsy’ cfDNA panel (MSK-ACCESS) for cancer detection, surveillance, and treatment selection and monitoring. In my talk, I will describe the prevalence of somatic and germline genomic alterations in a real-world population, the clinical benefits of cfDNA assessment, and how clonal hematopoiesis can inform cancer risk and confound liquid biopsy approaches to cancer detection.

 

ABOUT
Michael Berger, PhD, holds the Elizabeth and Felix Rohatyn Chair and is Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center, a multidisciplinary initiative to promote precision oncology through genomic analysis to guide the diagnosis and treatment of cancer patients. He is also an Associate Attending Geneticist in the Department of Pathology with expertise in cancer genomics, computational biology, and high-throughput DNA sequencing technology. His laboratory is developing experimental and computational methods to characterize the genetic makeup of individual cancers and identify genomic biomarkers of drug response and resistance. As Scientific Director of Clinical NGS in the Molecular Diagnostics Service, he oversees the development and bioinformatics associated with clinical sequencing assays, and he helped lead the development and implementation of MSK-IMPACT, a comprehensive FDA-authorized tumor sequencing panel that been used to profile more than 60,000 tumors from advanced cancer patients at MSK. The resulting data have enabled the characterization of somatic and germline biomarkers across many cancer types and the identification of mutations associated with clonal hematopoiesis. Dr. Berger also led the development of a clinically validated plasma cell-free DNA assay, MSK-ACCESS, which his laboratory is using to explore tumor evolution, acquired drug resistance, and occult metastatic disease. He received his Bachelor’s Degree in Physics from Princeton University and his Ph.D. in Biophysics from Harvard University.

 

Hosted by: Utkan Demirci, Ph.D.
Spon
sored by: The Canary Center & the Department of Radiology 
Stanford University – School of Medicine

Oct
12
Tue
2021
Cancer Early Detection Seminar Series - Azra Raza, MD @ Venue coming soon!
Cancer Early Detection Seminar Series – Azra Raza, MD
Oct 12 @ 11:00 am – 12:00 pm Venue coming soon!
Cancer Early Detection Seminar Series - Azra Raza, MD @ Venue coming soon!

CEDSS: The First Cell: A new model for cancer research and treatment

Azra Raza, M.D.
Chan Soon-Shiong Professor of Medicine
Director, Myelodysplastic Syndrome Center
Columbia University Medical Center

 

Location: Zoom
Meeting URL: https://stanford.zoom.us/s/99340345860
Dial: US: +1 650 724 9799  or +1 833 302 1536 (Toll Free)
Meeting ID: 993 4034 5860
Passcode: 711508

RSVP Here

 

ABSTRACT

Cancer research continues to be predicated on a 1970’s model of research and treatment. Despite half a century of intense research, we are failing spectacularly to improve the outcome for patients with advanced disease. Those who are cured continue to be treated mostly with the older strategies (surgery-chemo-radiation). Our contention is that the real solution to the cancer problem is to diagnose cancer early, at the stage of The First Cell. The rapidly evolving technologies are doing much in this area but need to be expanded. We study a pre-leukemic condition called myelodysplastic syndrome (MDS) with the hope that we can detect the first leukemia cells as the disease transforms to acute myeloid leukemia (AML). Towards this end, we have collected blood and bone marrow samples on MDS and AML patients since 1984. Today, our Tissue Repository has more than 60,000 samples. We propose novel methods to identify surrogate markers that can identify the First Cell through studying the serial samples of patients who evolve from MDS to AML.

 

ABOUT

Dr. Raza is a Professor of Medicine and Director of the MDS Center at Columbia University in New York, NY.She started her research in Myelodisplastic Syndromes (MDS) in 1982 and moved to Rush University, Chicago, Illinois in 1992, where she was the Charles Arthur Weaver Professor in Oncology and Director, Division of Myeloid Diseases. The MDS Program, along with a Tissue Repository containing more than 50,000 samples from MDS and acute leukemia patients was successfully relocated to the University of Massachusetts in 2004 and to Columbia University in 2010.

Before moving to New York, Dr. Raza was the Chief of Hematology Oncology and the Gladys Smith Martin Professor of Oncology at the University of Massachussetts in Worcester. She has published the results of her laboratory research and clinical trials in prestigious, peer reviewed journals such as The New England Journal of Medicine, Nature, Blood, Cancer, Cancer Research, British Journal of Hematology, Leukemia, and Leukemia Research. Dr. Raza serves on numerous national and international panels as a reviewer, consultant and advisor and is the recipient of a number of awards.

 

Hosted by: Utkan Demirci, Ph.D.
Spon
sored by: The Canary Center & the Department of Radiology 
Stanford University – School of Medicine